Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Micro Penny Stocks, Penny Stocks $0.10 & Under » PLRS-Bottom + news

 - UBBFriend: Email this page to someone!    
Author Topic: PLRS-Bottom + news
R.A.
Member


Rate Member
Icon 1 posted      Profile for R.A.     Send New Private Message       Edit/Delete Post   Reply With Quote 
Avg Vol (3m): 9,006,320

Last Trade: 0.0191 as of october 30th

52wk Range: 0.02 - 0.15

Chart:http://stockcharts.com/h-sc/ui?s=PLRS

Might be a good one for today.


Press Release Source: DynTek, Inc.


DynTek Acquires Sensible Security Solutions
Tuesday October 31, 7:30 am ET
Company Brings $7.0 million Revenue Stream, Enhanced Security Support Solutions and Critical Mass in the Canadian Market


IRVINE, Calif., Oct. 31 /PRNewswire-FirstCall/ -- DynTek, Inc. (OTC Bulletin Board: DYNK - News), a leading provider of professional technology solutions, today announced it has acquired the assets and operations of Sensible Security Solutions, based in Ottawa, Ontario.
ADVERTISEMENT



Founded in 1995, Sensible Security Solutions assists major Canadian organizations, both in the private and public sector, with the design and implementation of comprehensive, enterprise-level security solutions. In addition to professional technology services, SSS provides security support services 24x7, through online, phone and email support using a centralized customer service center in Ottawa, Ontario. For the twelve months ended June 30, 2006, SSS realized revenues in excess of $7.0US million.

Paul Saucier, president of Sensible Security Solutions will serve as president of DynTek Canada, Inc. "SSS is excited about the opportunity to broaden the reach of our highly scalable security support services to DynTek's operations throughout Canada and the United States," said Saucier. "We have garnered a reputation for being a premiere security solutions provider, and look forward to integrating with DynTek to build upon our leading position in the Canadian security market."

"This acquisition will strengthen DynTek Canada's security services practice and bring a new value-add to the DynTek customer base -- a comprehensive security support service and help desk," said Casper Zublin, Jr., DynTek's chief executive officer. "SSS's strong client relationships and vendor partnerships within the Canadian security market, coupled with our existing Toronto operations, will enable DynTek to achieve a critical mass in the Canadian market."

About DynTek

DynTek is a leading provider of professional technology services to mid- market companies, such as state and local governments, educational institutions and commercial entities in the largest IT markets nationwide. The company offers technology practices in IT security, advanced network infrastructure, voice over internet protocol ("VOIP"), and access infrastructure. DynTek's multidisciplinary approach allows our clients to turn to a single source for their most critical technology requirements. For more information, visit www.dyntek.com.

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that certain statements in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risks, uncertainties and other factors. Such uncertainties and risks include, among others, our ability to renew contracts with customers of Sensible Security Solutions; success in reaching target markets for services and products in a highly competitive market and the ability to maintain existing and attract future customers; the ability to finance and sustain operations, including the ability to comply with the terms of working capital facilities and/or other term indebtedness of the Company, and to extend such obligations when they become due, or to replace them with alternative financing; the ability to raise equity capital in the future; the ability to achieve profitability despite historical losses from operations; the ability to maintain business relationships with IT product vendors and the ability to procure products as necessary; the size and timing of additional significant orders and their fulfillment; the continuing desire of and available budgets for state and local governments to outsource to private contractors; the ability to successfully identify and integrate acquisitions; the retention of skilled professional staff and certain key executives; the performance of the Company's government and commercial technology services; the continuation of general economic and business conditions that are conducive to outsourcing of IT services; the ability to maintain trading on the NASD OTC Bulletin Board or other markets in the future; and such other risks and uncertainties included in our Annual Report on Form 10-K filed on October 13, 2006, and other SEC filings. The Company has no obligation to publicly release the results of any revisions, which may be made to any forward-looking statements to reflect anticipated or unanticipated events or circumstances occurring after the date of such statements.


--------------------------------------------------------------------------------
Source: DynTek, Inc.

Posts: 819 | Registered: Apr 2006  |  IP: Logged | Report this post to a Moderator
R.A.
Member


Rate Member
Icon 1 posted      Profile for R.A.     Send New Private Message       Edit/Delete Post   Reply With Quote 
Sorry wrong PR!


Press Release Source: Pluristem Life Systems, Inc.


Pluristem Expects to Submit Pre-IND Document to FDA by End of 2006
Tuesday October 31, 7:30 am ET


HAIFA, Israel--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB: PLRS - News), a cell therapy company dedicated to the commercialization of stem cell products, today announced that it expects to submit the Pre-Investigational New Drug (Pre-IND) document describing the suggested clinical trial and the preclinical data to the FDA by the end of the 4th quarter Of 2006. Approval of the Pre-IND by the FDA precedes initiation of Phase I trials.
ADVERTISEMENT



Pluristem recently presented a Pre-Pre-IND to the Center for Biologics Evaluation and Research (CBER), Office of Cellular, Tissue and Gene Therapies, a department in the Food and Drug Administration (FDA). The Pre-Pre-IND documented the final results of an animal model study using the Company's innovative adjuvant cell therapy product based on PLacenta eXpanded Mesenchymal cells (PLX-I).

In the Pre-Pre-IND conference call following the submission of the document, the FDA team of experts and the Pluristem FDA team discussed the proposed structure of the clinical trial, and the pre-clinical data required to approve the initiation of Phase I clinical trials of PLX-I. The FDA and Pluristem agreed that the proposed structure of Pluristem's Phase I study should document the safe use of PLX-I cells when combined with Umbilical Cord Blood (UCB), and how the combination could improve the treatment of blood disorders.

In the upcoming Pre-IND filing, Pluristem will present to the FDA CBER team the results of an additional agreed upon pre-clinical Animal trial. This additional pre-clinical animal trial will be performed on immune-deficient irradiated NOD-SCID mice which will be co-implanted with un-purified human umbilical cord blood cells and PLX-I. The conclusions will be held in comparison to Pluristem's published Pre-clinical results that used CD34+ purified from human umbilical cord blood cells. This additional trial will determine the final structure of the pre-clinical data required for FDA approval of the IND application.

Mr. Zami Aberman, Pluristem CEO, stated: "We would like to thank the CBER team for the very productive discussion. We expect to demonstrate that the co-transplantation of PLX-I cell types are a promising manipulation that improves cord blood performance during the replacement of bone marrow transplants in adults. I believe that this new pre-clinical animal trial will help to finalize the required pre-clinical studies prior to moving to Phase I trials."

About Pluristem

Pluristem Life Systems, Inc. is a life sciences driven company that is developing and commercializing stem cell expansion technology products for the treatment of severe blood disorders. The Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a proprietary bioreactor mimicking different naturally occurring physiological environments. Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. Its first adult stem cell product targets a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. The Company has made a strategic decision to work only with adult stem cells since the practical use of embryonic stem cells is severely restricted by various religious, ethical and legal considerations.

www.pluristem.com

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include statements: Pluristem expects to submit their Pre-Investigational New Drug (Pre-IND) Application to the Food and Drug Administration (FDA) by the end of the 4th Quarter, the FDA and Pluristem agreed that the proposed structure of Pluristem's Phase I study should document the safe use of PLX-I cells when combined with Umbilical Cord Blood (UCB), and how the combination could improve the treatment of blood disorders, in the upcoming Pre-IND filing, the additional trial will determine the final structure of the pre-clinical data required for FDA approval of the Pre-IND application, we expect to demonstrate that the co-transplantation of PLX-I cell types are a promising manipulation that improves cord blood performance during the replacement of bone marrow transplants in adults, that this new pre-clinical animal trial will help to finalize the required pre-clinical studies prior to moving to Phase 1 trials, the Company is discovering and developing cell-based therapeutics that utilizes adult stem cells expanded in a proprietary bioreactor mimicking different naturally occurring physiological environments, Pluristem expects its first products to be cell grafts that will provide an efficient and superior alternative to the standard procedure of bone marrow transplantation. Its first adult stem cell product is intended to target a critical global shortfall of matched tissue for bone marrow transplantation since bone marrow transplantation is often the only cure for patients suffering from leukemia, lymphoma, myeloma and many other hematological diseases. Factors which may significantly change or prevent our forward looking statements from fruition include that we may be unsuccessful in developing any products; that our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; that we are unable to retain or attract key employees whose knowledge is essential to the development of our products; that unforeseen scientific difficulties develop with our process; that results in the laboratory do not translate to equally good results in real surgical settings; that our patents are not sufficient to protect essential aspects of our technology; that competitors may invent better technology; that our products may not work as well as hoped or worse, that our products may harm recipients; and that we may not be able raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.


Contact:
Emerson Gerard Associates, Inc.
Media Contact
Jerry Jennings, 561-881-7318
mediareply*emersongerard.com
or
The PMH Group
Investors Contact
Paul Holm, 212-496-7238
pmhgroupinc*aol.com

--------------------------------------------------------------------------------
Source: Pluristem Life Systems

Posts: 819 | Registered: Apr 2006  |  IP: Logged | Report this post to a Moderator
R.A.
Member


Rate Member
Icon 1 posted      Profile for R.A.     Send New Private Message       Edit/Delete Post   Reply With Quote 
Ignore that thread, there's another one already that has been created by superman.
Posts: 819 | Registered: Apr 2006  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share